Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K
Cyxone (publ) announces today that the company has engaged a renowned European Contract Development & Manufacturing Organization (CDMO) for the scale-up and production of the active ingredient of its drug candidate T20K. The production will be performed in accordance with Good Manufacturing Practice (GMP), exploring a brand-new manufacturing method. The collaboration will initially cover method development and later supply material for use in non-clinical and clinical development activities.Cyxone is developing T20K, a peptide aimed for the treatment of multiple sclerosis (MS). Preclinical